About Us

YARAL Pharma Inc. is the U.S. generics subsidiary of IBSA (Institut Biochimique SA) — a leading multinational pharmaceutical company headquartered in Lugano, Switzerland.

Our Parent Company IBSA is:

Recognized as a world leader in the development of innovative technologies and products that improve the health and wellness of people.
Known for its manufacturing expertise and decades-long track record of product quality and supply continuity.
Continually building a wide-ranging portfolio of products across brands and generics in ten core therapeutic areas.

YARAL Pharma Company Pillars

Our Mission

As the generics division of IBSA Pharma, we are dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes.

Our Values & Expertise

By focusing on people and innovating the ways they’re cared for, we are proud to offer the same values and expertise of our parent company to the US market. 

Our Exceptional Customer Care

YARAL offers customers high-quality products, continuity of supply and a commitment to exceptional customer service.

Leadership Team

YARAL Pharma is led by a team of seasoned industry veterans, and supported by the YARAL Pharma Board of Directors, which includes members of IBSA’s leadership team. Drawing on the strengths and expertise of our parent company, YARAL Pharma’s leadership is dedicated to delivering high-quality products across diverse therapeutic areas, ensuring a reliable supply chain, and maintaining a high level of customer service.

YARAL Pharma Leadership Team

Stephen Beckman

Chief Executive Officer

Roberto Marrero

Chief Financial Officer

Steven Jordan

Director of Commercial Operations

Joseph Hodge

Vice President of Sales

Bill Punia

Vice President of
Supply Chain and Logistics

Benjamin M. Platek

Director of Human Resources

Avery Yuan

Manager of Business Analytics and Planning

Daniel Catalano

Senior Manager Finance

YARAL Pharma Board of Directors

Arturo Licenziati – President & CEO, IBSA Institut Biochimique SA
Nicholas Hart – CEO and Officer, IBSA Pharma Inc.
Stephen Beckman – CEO, YARAL Pharma Inc.
Luca Grassi – CFO, IBSA Institut Biochimique SA
Elisabetta Racca – Head of Legal Affairs, IBSA Institut Biochimique SA

A Look Ahead

YARAL Pharma is poised for continued growth, driven by a steadfast commitment to expanding access to high-quality generics and forming strategic partnerships. Building on the success of recent product launches and our strong relationships with trusted partners, YARAL is focused on building its product portfolio and extending its reach across new therapeutic areas.

As the generics industry evolves, we remain agile, prioritizing the inclusion of the right products in our portfolio to meet the diverse needs of our customers. Our vision for the future is clear: to grow strategically by collaborating with key industry partners, ensuring that we continue to deliver exceptional value to our customers and patients nationwide.